Lumos Pharma Inc

NASDAQ:LUMO  
9.89
+0.13 (+1.33%)
Earnings Announcements

Lumos Pharma Reports Full Year 2020 Financial Results

Published: 03/09/2021 23:03 GMT
Lumos Pharma Inc (LUMO) - Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on Oragrowth Trials in Pghd.
Lumos Pharma - Expects Cash on Hand Sufficient to Fund Current Operations Through Read-out of Phase 2b Oragrowth210 Trial, Completion of Oragrowth212 Trial.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.90

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.94

More details on our Analysts Page.